Lung Cancer | Clinical

Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC

November 26, 2022

Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.

Nadler Reviews Targeted Therapy for EGFR Exon 20 Insertion NSCLC

November 21, 2022

During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Reflex Testing of Next Generation Sequencing (NGS)-Based Panels in NSCLC

November 17, 2022

Nurse Practitioner Lauren Welch and Dr Michelle Shiller share whether next-generation sequencing is reflexively ordered at their institutions, turnaround times for this type of testing, and which panels they typically choose.